P
Philippe Chollet
Researcher at French Institute of Health and Medical Research
Publications - 107
Citations - 6482
Philippe Chollet is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 36, co-authored 107 publications receiving 5965 citations. Previous affiliations of Philippe Chollet include University of Auvergne.
Papers
More filters
Journal ArticleDOI
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
Sylvie Giacchetti,B. Perpoint,Rachid Zidani,N. Le Bail,R. Faggiuolo,Christian Focan,Philippe Chollet,J.F. Llory,Y. Letourneau,Bruno Coudert,F. Bertheaut-Cvitkovic,D. Larregain-Fournier,A. Le Rol,Stephen D. Walter,Rosalyn M. Adam,J.L. Misset,Francis Lévi +16 more
TL;DR: By chronomodulating 5-FU-LV, the authors were able to add l-OHP without compromising dose-intensities and significantly improved the antitumor efficacy of this regimen.
Journal ArticleDOI
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
Javier Cortes,Joyce O'Shaughnessy,David Loesch,Joanne L. Blum,Linda T. Vahdat,Katarina Petrakova,Philippe Chollet,Alexey Manikas,Véronique Diéras,Thierry Delozier,Vladimir Vladimirov,Fatima Cardoso,Han Koh,Philippe Bougnoux,Corina E. Dutcus,Seth Seegobin,Denis Mir,Nicole Meneses,Jantien Wanders,Chris Twelves +19 more
TL;DR: Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer, challenging the notion that improved overall survival is an unrealistic expectation during evaluation of new anticancer therapies in the refractory setting.
Journal ArticleDOI
Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial
Francis Lévi,Rachid Zidani,J.-M. Vannetzel,B. Perpoint,Christian Focan,R. Faggiuolo,Philippe Chollet,Carlo Garufi,M. Itzhaki,L Dogliotti +9 more
TL;DR: This ambulatory treatment modality was both more effective and less toxic if drug delivery was chronomodulated rather than constant over time, as determined in another trial in patients with previously untreated metastatic colorectal cancer.
Journal ArticleDOI
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Mathilde Bayet-Robert,Fabrice Kwiatkowski,Marianne Leheurteur,Françoise Gachon,Eloise Planchat,Catherine Abrial,Marie-Ange Mouret-Reynier,Xavier Durando,Chantal Barthomeuf,Philippe Chollet +9 more
TL;DR: The maximal tolerated dose of the combination of dose-escalating curcumin and standard dose of docetaxel chemotherapy in advanced and metastatic breast cancer patients was determined at 8000 mg/d, with encouraging efficacy results.
Journal ArticleDOI
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
Francis Lévi,B. Perpoint,Carlo Garufi,Christian Focan,Philippe Chollet,Petra Deprés-Brummer,Rachid Zidani,S. Brienza,M. Itzhaki,Stefano Iacobelli,Francis Kunstlinger,J. Gastiaburu,Jean Louis Misset +12 more
TL;DR: This phase II trial has tested the antitumour activity of a 5-day circadian schedule of continuous venous infusion of L-OHP against metastatic colorectal cancer, and results support the place of L.OHP in combination regimens including 5-fluorouracil.